enVVeno MedicalNVNO
About: enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Employees: 37
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
528% more call options, than puts
Call options by funds: $289K | Put options by funds: $46K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 36 [Q3] → 35 (-1) [Q4]
14.78% less ownership
Funds ownership: 39.09% [Q3] → 24.31% (-14.78%) [Q4]
26% less capital invested
Capital invested by funds: $17.5M [Q3] → $12.9M (-$4.62M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NVNO.
Financial journalist opinion









